Actemra Market, By Indication (Rheumatoid Arthritis, Giant Cell Arteritis (GCA), Polyarticular Juvenile Idiopathic Arthritis (PJIA), Systemic Juvenile Idiopathic Arthritis (SJIA), Cytokine Release Syndrome (CRS), and Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD)), By Strength (80 mg/4 mL (20 mg/mL), 200 mg/10 mL (20 mg/mL), 400 mg/20 mL (20 mg/mL), and 162 mg/0.9 mL for Injection), By Packaging (Single-dose vials and Single-dose prefilled syringe or autoinjector), By Route of Administration (Subcutaneous and Intravenous), By Age Group (Adult, Pediatric, and Geriatric), By Sales Channel (Online and Offline), By End User (Hospitals, Specialized Infusion Centers, and Others (Academics and Research Institutes, etc.)), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)
선택하다 귀사의 비즈니스 요구 사항에 맞는 라이센스 유형
US$ 2,200
이천이백 달러
단일 사용자 라이센스
( 전체 보고서 )
US$ 4,500
US$ 3,000
Three thousand dollars
자주 구매되는 상품
다중 사용자 라이센스
(전체 보고서)
US$ 7,000
US$ 5,000
Five thousand dollars
기업 사용자 라이센스
(전체 보고서)
US$ 10,000
US$ 6000
Six thousand dollars
Client Testimonials
Client Testimonials
우리의 고객